446263-96-3 Usage
Uses
Used in Research Applications:
3-(6-aminopyridin-3-yl)propanoic acid is utilized as a research chemical for studying its potential biological activity and interactions with biological systems. Its structural features may offer insights into the development of new pharmaceutical compounds or the understanding of certain biochemical processes.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 3-(6-aminopyridin-3-yl)propanoic acid is used as a starting material or intermediate in the synthesis of drug candidates. Its unique structure may contribute to the development of novel therapeutic agents with specific targeting or modulating properties.
Used in Chemical Synthesis:
3-(6-aminopyridin-3-yl)propanoic acid serves as a building block in the synthesis of various organic compounds and complex molecules. Its reactivity and functional groups can be exploited in organic synthesis to create new chemical entities with potential applications in different fields.
Check Digit Verification of cas no
The CAS Registry Mumber 446263-96-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,6,2,6 and 3 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 446263-96:
(8*4)+(7*4)+(6*6)+(5*2)+(4*6)+(3*3)+(2*9)+(1*6)=163
163 % 10 = 3
So 446263-96-3 is a valid CAS Registry Number.
446263-96-3Relevant academic research and scientific papers
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)
Miller, William H.,Seefeld, Mark A.,Newlander, Kenneth A.,Uzinskas, Irene N.,Burgess, Walter J.,Heerding, Dirk A.,Yuan, Catherine C. K.,Head, Martha S.,Payne, David J.,Rittenhouse, Stephen F.,Moore, Terrance D.,Pearson, Stewart C.,Berry, Valerie,DeWolf Jr., Walter E.,Keller, Paul M.,Polizzi, Brian J.,Qiu, Xiayang,Janson, Cheryl A.,Huffman, William F.
, p. 3246 - 3256 (2007/10/03)
Bacterial enoyl-ACP reductase (FabI) catalyzes the final step in each cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. Our efforts to identify potent, selective FabI inhibitors began w
